Sevuparin sodium Drug Asset Due Diligence Report 2026

This Sevuparin sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Sevuparin sodium can convert its Polymer profile and Heparin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Sevuparin sodium (query alias: Sevuparin sodium)
Modality / target	Polymer; Heparin; Heparin agonists
Highest global status	Phase 2
Originator	Dilafor AB
Active developers	Modus Therapeutics AB, Dilafor AB, Università degli Studi di Brescia

The MCP disease footprint includes chronic renal failure anemia, Malaria, Falciparum, Sepsis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NL-OMON52250	Not Applicable	Completed	64	Primary endpoint not disclosed in English source
ISRCTN32271864	Phase 1	Ongoing	20	Primary endpoint not disclosed in English source
PACTR202007890194806	Phase 1	Recruiting	20	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Modus Therapeutics on track to initiate Part 2 of Phase IIa sevuparin study in CKDrelated anemia

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: AE = with no discontinuations due to adverse events, and no observed clinically significant safety trends.

Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Phase 2; n=144; evaluation: Negative. Reported fields: Median time to vaso-occlusive crisis resolution = 100.4 Hour (95%CI, 85.5 - 116.8); Median time to vaso-occlusive crisis resolution = 86.4 Hour (95%CI, 70.6 - 95.1)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Sevuparin sodium addresses chronic renal failure anemia, Malaria, Falciparum, Sepsis. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Polymer—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “target-level comparable: Heparin.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Heparin records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-01-21	Karolinska Development’s portfolio company Dilafor signs binding term sheet with Exeltis for a license agreement regarding tafoxiparin	Phase 2	Financial terms not disclosed
2014-02-20	Dilafor enters into a license and partnership agreement with Lee’s Pharmaceutical	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “New medical use of sevuparin in the treatment of endotoxemia”. The milestone feed surfaced a patent-application signal described as “Sevuparin for the treatment of chronic kidney disease”. The milestone feed surfaced a patent-application signal described as “Use of chemically modified heparin derivates in sickle cell disease”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO